fda warning on semaglutide Approves for New Indication Involving Cardiovascular Disease FDA Drug Recalls and Warnings:

In practical terms, this means: Sources: SURMOUNT-5 Trial, NEJM 2025

A 6-week protocol at 0.25 mg daily requires approximately 10.5 mg, meaning two to three vials covers a standard cycle

available only through 503A compounding or research supply SNRI drugs covered / venlafaxine (Effexor XR) and duloxetine (Cymbalta) Primary interaction concern / overlapping serotonergic and vasopressive effects DDI severity grading / not classifiable (no human PK/PD interaction studies exist) Serotonin syndrome incidence with SNRI monotherapy / estimated 0.07 per 1,000 patient-years per pharmacovigilance data Venlafaxine CYP pathway / CYP2D6 (major), CYP3A4 (minor) Duloxetine CYP pathway / CYP1A2 (major), CYP2D6 (moderate) BPC-157 CYP interaction profile / unknown in humans

Researchers call it a potential game changer, especially for those whose high blood pressure persists despite treatment

The recommended dosage for Semaglutide is as follows: 0.25 mg once weekly for the first 4 weeks 0.5 mg once weekly for at least 4 weeks 1 mg once weekly for at least 4 weeks, but only if additional glycemic control is needed 2mg once weekly if additional control is needed Semaglutide injections should be dosed subcutaneously